Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 1, 1996, Pages 53-59

  Benedict, Claude R ^a,d   Arbogast, Robert ^b   Martin, Lorene ^c   Patton, Lavonne ^c   Morrill, Bruce ^c   Hahne, William ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c SANOFI   (France)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

5 HT3 Receptor antagonists; Dolasetron; ECG intervals; Ondansetron

Indexed keywords

DOLASETRON MESILATE; ONDANSETRON; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEART DEPOLARIZATION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOLUNTEER;

ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; ONDANSETRON; QUINOLIZINES; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0029898199     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199607000-00009     Document Type: Article

References (31)

1. Kovac AL. Use of serotonin receptor antagonists in the prevention and treatment of nausea and vomiting. Hosp Formulary 1993;28:988-98.
2. Soukou M. 5-Hydroxytryptamine antagonists: a new class of potent antiemetics in cancer therapy. Recent Results Cancer Res 1991;121:86-90.
3. Galvan M, Gittos MW, Fatmi M. Dolasetron mesylate. Drugs Future 1993;18:506-9.
4. 3 receptors. Drug Dev Res 1993;28:87-93.
5. Heck K, Holmes GB, Adams MA, Hunt TL, Hahne W. A double-blind, placebo-controlled, dose-rising tolerance study of intravenous MDL 73,147EF in normal volunteers [Abstract]. Clin Pharmacol Ther 1992;51:186.
6. Dixon R, Cramer M, Conway DW, et al. Single-dose, pla cebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996;16:245-52.
7. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994;17:97-102.
8. Kris MG, Grunberg SM, Gralla RJ, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994;12: 1045-9.
9. 3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993;4:481-4.
10. Kasimis B, Tapazoglou EI, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high-dose cisplatin (CDDP) chemotherapy [Abstract 1538]. Proc Am Soc Clin Oncol 1994;13:446.
11. 2) cisplatin (CDDP) containing chemotherapy [Abstract]. Proc Am Soc Clin Oncol 1994;13:445.
12. Baltzer L, Kris MG, Hinkley L, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug effect without sequelae? [Abstract]. Proc Am Soc Clin Oncol 1994;13:433.
13. Lifsey DS, Gralla RJ, Clark RA, Kline RC. Electrocardiographic changes with serotonin antagonist antiemetics: rates of occurrence and clinical relevance [Abstract]. Proc Am Soc Clin Oncol 1993;12:463.
14. Rusthoven J, Pater J, Kaizer L, et al. A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1991;2:681-6.
15. Wantanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-82.
16. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res 1991;24:277-84.
17. 3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol 1994;113:527-35.
18. Scholtysik G. Evidence for inhibition by ICS 205-930 and stimulations by BRL 34915 of K + conductance in cardiac muscle. Arch Pharmacol 1987;335:692-6.
19. Dumaine R, Hartmann HA, Leishman DJ, Brown AM, Galvan M. Actions of dolasetron and its major metabolite on guinea pig papillary muscle fibres and the α-subunit of human heart sodium channels expressed in Xenopus oocytes. Drug Dev Res (in press).
20. 3 receptor antagonists? Antiemetic control: maximizing the benefits. Satellite symposium, 7th European Conference on Clinical Oncology and Cancer Nursing (ECCO), November 14, 1993, Jerusalem, Israel.
21. Hersh MR, Linn W, Kuhn JG, et al. Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy. Cancer Treat Rep 1986;70:349-52.
22. Cappelaere P, Vincent A, Starmont M, et al. Continuous Holter cardiac monitoring in patients given cisplatin and fluoro-uracil combination therapy. Bull Cancer 1991;78:261-72.
23. Friess GG, Boyd JF, Geer MR, et al. Effects of first dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring. Cancer 1985;56:2762-4.
24. Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987;60:1213-8.
25. Andrews PLR, Hawthorn J. The neurophysiology of vomiting. Bailllieres Clin Gastroenterol 1988;2:141-68.
26. Lewis NP, Fraser AG, Taylor A. Syncope while vomiting during migraine attack. Lancet 1988:2:400-1.
27. Mehta D, Saverymuttu SH, Camm AJ. Recurrent paroxysmal complete heart block induced by vomiting. Chest 1988;94:433-5.
28. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF. A double-blind, placebo-controlled, dose-ranging safety and pharmacology evaluation of single-dose dolasetron in healthy male volunteers. J Clin Pharmacol 1995;35:705-12.
29. Osborne RJ, Slevin ML, Hinter RW, et al. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Human Toxicol 1985;4:617-23.
30. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics: I. disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
31. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.